These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
362 related articles for article (PubMed ID: 19945685)
1. Strategies for treatment to prevent fragility fractures in postmenopausal women. Geusens P Best Pract Res Clin Rheumatol; 2009 Dec; 23(6):727-40. PubMed ID: 19945685 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis. Iwamoto J; Takeda T; Sato Y Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313 [TBL] [Abstract][Full Text] [Related]
6. Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial. Reginster JY; Felsenberg D; Boonen S; Diez-Perez A; Rizzoli R; Brandi ML; Spector TD; Brixen K; Goemaere S; Cormier C; Balogh A; Delmas PD; Meunier PJ Arthritis Rheum; 2008 Jun; 58(6):1687-95. PubMed ID: 18512789 [TBL] [Abstract][Full Text] [Related]
7. Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX. Kanis JA; Johansson H; Oden A; McCloskey EV Bone; 2009 Jun; 44(6):1049-54. PubMed ID: 19254788 [TBL] [Abstract][Full Text] [Related]
8. Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause; 2010; 17(1):25-54; quiz 55-6. PubMed ID: 20061894 [TBL] [Abstract][Full Text] [Related]
9. Primary care use of FRAX: absolute fracture risk assessment in postmenopausal women and older men. Siris ES; Baim S; Nattiv A Postgrad Med; 2010 Jan; 122(1):82-90. PubMed ID: 20107292 [TBL] [Abstract][Full Text] [Related]
10. Osteoporosis: from early fracture prevention to better bone health with strontium ranelate. Cortet B Rheumatology (Oxford); 2009 Oct; 48 Suppl 4():iv14-9. PubMed ID: 19783589 [TBL] [Abstract][Full Text] [Related]
12. FRAX and its applications in health economics--cost-effectiveness and intervention thresholds using bazedoxifene in a Swedish setting as an example. Ström O; Borgström F; Kleman M; McCloskey E; Odén A; Johansson H; Kanis JA Bone; 2010 Aug; 47(2):430-7. PubMed ID: 20493983 [TBL] [Abstract][Full Text] [Related]
13. [How to prevent early postmenopausal fracture risk? Proposition of a strategy]. Trémollieres F; Pouilles JM; Ribot C Gynecol Obstet Fertil; 2009 Jan; 37(1):50-6. PubMed ID: 19110461 [TBL] [Abstract][Full Text] [Related]
14. Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial. Ensrud KE; Black DM; Palermo L; Bauer DC; Barrett-Connor E; Quandt SA; Thompson DE; Karpf DB Arch Intern Med; 1997 Dec 8-22; 157(22):2617-24. PubMed ID: 9531231 [TBL] [Abstract][Full Text] [Related]
15. Recognition of women at risk for fracture and intervention with fast-acting therapies. Derman R Int J Fertil Womens Med; 2006; 51(4):183-90. PubMed ID: 17184104 [TBL] [Abstract][Full Text] [Related]
16. New possibilities for diagnosis and treatment of osteoporosis. Miller PD Int J Fertil Womens Med; 2001; 46(4):215-21. PubMed ID: 11563832 [TBL] [Abstract][Full Text] [Related]
17. Health-economic comparison of three recommended drugs for the treatment of osteoporosis. Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171 [TBL] [Abstract][Full Text] [Related]
18. Continuous broad protection against osteoporotic fractures with strontium ranelate. Ferrari S Rheumatology (Oxford); 2009 Oct; 48 Suppl 4():iv20-4. PubMed ID: 19783590 [TBL] [Abstract][Full Text] [Related]
19. Protelos: nonvertebral and hip antifracture efficacy in postmenopausal osteoporosis. Adami S Bone; 2006 Feb; 38(2 Suppl 1):23-7. PubMed ID: 16434247 [TBL] [Abstract][Full Text] [Related]
20. Trends and determinants of antiresorptive drug use for osteoporosis among elderly women. Perreault S; Dragomir A; Desgagné A; Blais L; Rossignol M; Blouin J; Moride Y; Ste-Marie LG; Fernandès JC Pharmacoepidemiol Drug Saf; 2005 Oct; 14(10):685-95. PubMed ID: 15645517 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]